| A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) NCT06101095 | Fase 4 | En marcha, sin reclutar |
| ENGAGE NCT05831176 | Fase 2 | En marcha, sin reclutar |
| A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab)) NCT05731128 | Fase 2 | En marcha, sin reclutar |
| OPALE NCT06393946 | no aplica | En marcha, sin reclutar |
| Dermatitis atópica NCT06415175 | no aplica | En marcha, sin reclutar |
| Dermatitis atópica NCT02612454 | Fase 3 | En marcha, sin reclutar |
| Asma NCT05097287 | Fase 4 | En marcha, sin reclutar |
| PROSE NCT03428646 | no aplica | En marcha, sin reclutar |
| Asma NCT06572228 | Fase 4 | En marcha, sin reclutar |
| PELISTAD-EX2 NCT05983068 | Fase 4 | En marcha, sin reclutar |
| Dermatitis atópica NCT07467564 | no aplica | Reclutando pacientes |
| ProMEAL NCT06695897 | no aplica | Reclutando pacientes |
| Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) NCT05263206 | Fase 3 | Reclutando pacientes |
| Prurigo nodular NCT06293053 | Fase 3 | Reclutando pacientes |
| Dermatitis atópica NCT06192563 | no aplica | Reclutando pacientes |
| Dermatitis atópica NCT06169527 | no aplica | En marcha, sin reclutar |
| EoE-TOTs NCT07112378 | Fase 3 | Reclutando pacientes |
| EPOC NCT07587658 | Fase 4 | Reclutando pacientes |
| Asma NCT06191315 | Fase 3 | Reclutando por invitación |
| EPOC NCT07053423 | Fase 4 | Reclutando pacientes |
| EPOC NCT07052396 | no aplica | Reclutando pacientes |
| EDESIA NCT06693531 | no aplica | En marcha, sin reclutar |
| Compassionate Use or Expanded Access of Dupilumab NCT04776694 | no aplica | Disponible por acceso ampliado |
| Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab NCT06631677 | no aplica | Disponible por acceso ampliado |
| BUILD-PEDS NCT07187089 | Fase 4 | Retirado antes de empezar |
| Prurigo nodular NCT05991323 | no aplica | Completado |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) NCT06687967 | Fase 3 | Completado |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) NCT06687980 | Fase 3 | Completado |
| Urticaria crónica espontánea NCT07316114 | no aplica | Interrumpido |
| Dermatitis atópica NCT03936335 | no aplica | Completado |
| Asma NCT04173442 | no aplica | Completado |
| Asma NCT03560466 | Fase 3 | Completado |
| DISCOVER NCT05590585 | Fase 4 | Completado |
| Urticaria crónica espontánea NCT05526521 | Fase 3 | Completado |
| Dupilumab in Chinese Adult Participants With CRSwNP NCT05878093 | Fase 3 | Completado |
| LIBERTY-BP NCT04206553 | Fase 2/3 | Completado |
| Dermatitis atópica NCT05624112 | Fase 4 | Completado |
| Dermatitis atópica NCT05680298 | Fase 4 | Completado |
| Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) NCT04442269 | Fase 2 | Completado |
| Asma NCT04203797 | Fase 4 | Completado |
| Asma NCT04400318 | Fase 4 | Completado |
| Dermatitis atópica NCT04287608 | no aplica | Completado |
| NEURADAD NCT05203380 | no aplica | Completado |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) NCT04417894 | Fase 3 | Completado |
| DIFFEREN-STAD NCT04823130 | Fase 4 | Completado |
| Dermatitis atópica NCT01949311 | Fase 3 | Completado |
| EoE KIDS NCT04394351 | Fase 3 | Completado |
| Dermatitis atópica NCT04033367 | Fase 4 | Completado |
| Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) NCT03633617 | Fase 3 | Completado |
| Liberty AD NCT03346434 | Fase 2/3 | Completado |
| Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy NCT03793608 | Fase 2 | Completado |
| Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) NCT03682770 | Fase 2 | Completado |
| Asma NCT02948959 | Fase 3 | Completado |
| Dermatitis atópica NCT03912259 | Fase 3 | Completado |
| Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) NCT03345914 | Fase 3 | Completado |
| Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy NCT03558997 | Fase 2 | Completado |
| Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis NCT03054428 | Fase 3 | Completado |
| Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis NCT03050151 | Fase 1 | Completado |
| Asma NCT02528214 | Fase 3 | Completado |
| Asma NCT02414854 | Fase 3 | Completado |